Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Alpine Immune Sciences, Inc.
< Previous
1
2
Next >
Alpine Immune Sciences Announces Participation in the Bank of America Securities Healthcare Conference
May 01, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
March 23, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data and Clinical Pharmacokinetic & Pharmacodynamic Modeling at Upcoming Scientific Conferences
March 20, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data at the 2023 American Academy of Dermatology Annual Meeting
March 16, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences to Report Fourth Quarter and Full Year 2022 Financial Results
March 15, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
February 28, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences to Participate in the SVB Securities Global Biopharma Conference
February 09, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Announces Participation in Fireside Chat at the 5th Annual Evercore ISI HealthCONx Conference
November 22, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 14, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences to Report Third Quarter 2022 Financial Results
November 07, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Presents Update Of ALPN-303 Phase 1 (RUBY-1) Clinical Data at the American Society of Nephrology Kidney Week 2022 Meeting
November 03, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at 2022 American Society of Hematology Annual Meeting & Exposition
November 03, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at Upcoming Scientific Conferences
October 26, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Terminates Enrollment of Davoceticept Clinical Studies (NEON-1 and NEON-2)
October 24, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Announces Pricing of $100 Million Public Offering
September 20, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Announces Proposed Public Offering
September 20, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences to Highlight Clinical Updates on Autoimmune and Immuno-Oncology Programs at Inaugural R&D Day
September 12, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Announces R&D Day to Provide Clinical Updates on Wholly-Owned Programs ALPN-303 and Davoceticept
August 30, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Announces Inducement Grant to Andrew S. Sandler, M.D. Under Nasdaq Listing Rule 5635(c)
August 18, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 11, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Announces Participation in Fireside Chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference
August 04, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Appoints Andrew S. Sandler, M.D. as Chief Medical Officer
June 07, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Announces Presentations at the 2022 EULAR and ASCO Annual Meetings
May 26, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab
May 24, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 12, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Announces Participation in May Investor Conferences
May 03, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Publishes Key Preclinical Rationale for Davoceticept (ALPN-202), a First-in-Class CD28 Costimulator and Dual Checkpoint Inhibitor, in Nature Communications
April 04, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences to Host Virtual Investor Event at 2022 AACR Annual Meeting
March 30, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
March 17, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Announces Participation in January Investor Conferences
January 04, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.